(Q36643657)

15 August 2017

1 reference

title

Rifapentine for the treatment of pulmonary tuberculosis (English)

1 reference

15 August 2017

1 reference

1 reference

Sonal S Munsiff

1

1 reference

15 August 2017

Chrispin Kambili

series ordinal

2

1 reference

15 August 2017

Shama Desai Ahuja

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

24 October 2006

1 reference

Clinical Infectious Diseases

15 August 2017

published in

1 reference

15 August 2017

volume

43

1 reference

15 August 2017

issue

11

1 reference

15 August 2017

page(s)

1468-1475

1 reference

Eleven years of community-based directly observed therapy for tuberculosis

15 August 2017

cites work

1 reference

Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel

21 January 2018

1 reference

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

21 January 2018

1 reference

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis

21 January 2018

1 reference

Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

21 January 2018

1 reference

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials

21 January 2018

1 reference

Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction

21 January 2018

1 reference

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

21 January 2018

1 reference

Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy

21 January 2018

1 reference

Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine

21 January 2018

1 reference

Relapse in persons treated for drug-susceptible tuberculosis in a population with high coinfection with human immunodeficiency virus in New York City

21 January 2018

1 reference

Relapse and acquired rifampin resistance in HIV-infected patients with tuberculosis treated with rifampin- or rifabutin-based regimens in New York City, 1997-2000.

21 January 2018

1 reference

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis

21 January 2018

1 reference

Potent twice-weekly rifapentine-containing regimens in murine tuberculosis

21 January 2018

1 reference

The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis

21 January 2018

1 reference

A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment

21 January 2018

1 reference

Influence of various diets on the bioavailability of isoniazid.

21 January 2018

1 reference

Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide

21 January 2018

1 reference

Clinical Pharmacokinetics of Rifampicin

21 January 2018

1 reference

Pharmacokinetics of rifapentine in children

21 January 2018

1 reference

Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model

21 January 2018

1 reference

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

21 January 2018

1 reference

Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic

21 January 2018

1 reference

Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/508278

1 reference

15 August 2017

1 reference